Ftse Mib
34.886,10
0,20%
DAX
18.702,77
-0,19%
S&P 500
5.221,42
-0,02%
NASDAQ
16.388,24
0,29%
Bitcoin
61.676,91
-1,95%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ YS Biopharma Company Ltd (YS) YS Biopharma Company Ltd (YS) Notizie

YS Biopharma Company Ltd

YS
0,9001
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 10:25:51
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
07/5/202422:20PRNUSYS Biopharma to Hold Extraordinary General Meeting on May..
29/4/202414:00PRNUSYS Biopharma Receives Additional 180 Day Extension by Nasdaq..
19/4/202413:00PRNUSYS Biopharma Announces Unaudited Financial Results for the..
18/4/202414:00PRNUSYS Biopharma Granted Phase I Clinical Trial License of..
16/4/202414:00PRNUSYS Biopharma to Report First Nine Months of Fiscal Year 2024..
09/4/202414:00PRNUSYS Biopharma Announces Positive Interim Results of Pivotal..
03/4/202414:00PRNUSYS Biopharma Announces Full Repayment of US$40,000,000 Loan..
05/3/202414:00PRNUSYS Biopharma Announces Board Changes and Strategic..
22/2/202423:00PRNUSYS Biopharma Announces Results of Extraordinary General..
18/2/202410:30PRNUS/C O R R E C T I O N -- YS Biopharma Co., Ltd./
17/2/202402:20PRNUSYS Biopharma Announces Results of Extraordinary General..
14/2/202414:00PRNUSYS Biopharma to Hold an Extraordinary General Meeting on..
14/2/202413:50PRNUSYS Biopharma Announces Appointment of New Directors
12/2/202414:50PRNUSYS Biopharma Responds to a Notice of Extraordinary General..
09/2/202412:30PRNUSYS Biopharma Announces US$40 Million Private Placement..
09/2/202400:10PRNUSShareholders of YS Biopharma Announce an Extraordinary..
22/1/202423:00PRNUSYS Biopharma Announces Unaudited Financial Results for the..
08/1/202414:00PRNUSYS Biopharma Announces Changes to its Board Committees
20/12/202322:30PRNUSYS Biopharma Responds to Unauthorized Press Release..
20/12/202314:56PRNUSYS Biopharma Co., Ltd. to Hold Extraordinary General Meeting..
14/11/202314:30PRNUSNoble Capital Markets Initiates Coverage on YS Biopharma..
31/10/202313:30PRNUSYS Biopharma Announces Completion of Subject Enrollment in..
26/10/202314:30PRNUSYS Biopharma Announces Receipt of Nasdaq Notice
26/9/202314:30PRNUSYS Biopharma Announces First Subject Enrollment in Pivotal..
15/9/202314:30PRNUSYS Biopharma Granted Patent in the U.S. for Immunotherapy..
05/9/202314:30PRNUSYS Biopharma to Participate in Participate in Citi's 18th..
24/8/202322:15PRNUSYS Biopharma Announces Purchase of Shares by Company..
15/8/202323:00PRNUSYS Biopharma Announces Unaudited Financial Results for the..
26/7/202323:00PRNUSYS Biopharma Announces Financial Results for Fiscal Year..
21/7/202322:30PRNUSYS Biopharma to Report Financial Results for Fiscal Year..
01/6/202314:30PRNUSYS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical..
18/5/202314:25PRNUSYS Biopharma to Participate in the Virtual Benchmark..
16/5/202313:00PRNUSYS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical..
Apertura: Min: Max:
Chiusura: 0,9001

La tua Cronologia

NASDAQ
YS
YS Biopharma
LSE
QM71
Morg.st.b.v 27
ASX
GVF
Staude Capital Global Va...
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network